Menu

Giant DNA Origami

Researchers create the largest 3-D DNA structures to date, many times bigger than previously constructed origami shapes.

Sep 18, 2014
Jef Akst

FLICKR, MEHMET PINARCIDNA origami, a strategy devised eight years ago by Paul Rothemund’s group at Caltech, allows researchers to link DNA scaffolds with smaller bits of the nucleic acid called staples to create desired shapes. The technique is now being used to develop drug-delivery systems and other molecular machines. But the most common technique—using an M13 bacteriophage to generate single-stranded DNA scaffolds of up to 7 kilobases—has restricted the size of the products to tens of square nanometers. Double-stranded DNA could be produced at longer lengths, but was limited in its ability to fold at a researchers’ will. Now, Thomas LaBean of North Carolina State University and colleagues have devised a solution: using a hybrid virus for DNA production, the researchers can generate scaffolds of up to 51 kilobases—and they’ve used these to create DNA structures that are hundreds of square nanometers in size, Chemical & Engineering News (C&EN) reported.

“They’ve achieved something people have been trying to do for a while,” Rothemund told C&EN.

To fold giant pieces of DNA, LaBean’s team used more than 1,600 staples. According to C&EN, such a task would have cost $7,000 using conventional DNA synthesis. So to reduce the cost, the team repurposed an ink-jet printer to synthesize the DNA, using reusable templates and chips with polymer micropillars, then amplified the produces using PCR.

“We had to do two things to make this viable,” lead author Alexandria Marchi of Duke University said in a press release. “First we had to develop a custom scaffold strand that contained 51 kilobases. . . . Second, in order to make this economically feasible, we had to find a cost-effective way of synthesizing staple strands—because we went from needing 220 staple strands to needing more than 1,600.”

Using these two DNA components, the team constructed notched rectangles with surface areas seven times bigger than similar structures made with traditional, M13 phage-produced scaffolds. The researchers reported their results this month (September 1) in Nano Letters.

“These origami can be customized for use in everything from studying cell behavior to creating templates for the nanofabrication of electronic components,” LaBean said in the release.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.